Source comparison
Ipamorelin Oral vs Injectable: Direct Comparison
The following table compares subcutaneous injectable ipamorelin against oral peptide formulations across the variables that determine research utility. Every claim is supported by published pharmacokinetic data or manufacturer specifications. Subcutaneous Inje
This comparison does not assign a generated winner or score.
- The following table compares subcutaneous injectable ipamorelin against oral peptide formulations across the variables that determine research utility. Every claim is supported by published pharmacokinetic data or manufacturer specifications.
- Subcutaneous Injectable
- 80–95%. Intact peptide reaches systemic circulation
- 24–36 months as lyophilised powder at −20°C; 28 days post-reconstitution at 2–8°C
- 30–45 minutes to Cmax
- ~2 hours in circulation before peptidase cleavage
- Industry standard for peptide research. Reproducible pharmacokinetics, verifiable purity, and proven receptor engagement in published trials.
- Oral Tablet/Capsule
- <1%. Majority degraded by gastric acid and pepsin before absorption
- 12–18 months at room temperature; purity loss accelerates with heat/humidity exposure
- No measurable plasma concentration in controlled studies
- Not applicable. Insufficient systemic exposure
- Marketed as "convenient alternative" but lacks pharmacological plausibility. Zero peer-reviewed trials demonstrating GH elevation from oral ipamorelin.
- Enteric-Coated Oral
- 1–3%. Coating delays gastric degradation but does not prevent intestinal peptidase cleavage
- 12–18 months; coating adds moisture-sensitive polymers that degrade in humid storage
- No measurable GH response in functional assays
- Not applicable
- Enteric coating solves the wrong problem. Gastric acid is one of four degradation barriers, and intestinal proteases remain unaddressed.
- The bottom line: injectable ipamorelin isn't a "better" version of oral. It's the only version with demonstrated biological activity. Every published GH secretagogue study citing ipamorelin as the test compound used subcutaneous or intravenous administration. Oral peptide products exist because consumer demand for "needle-free" options creates a market, not because the science supports efficacy.